AR058194A1 - Medicamentos que comprenden un agente antimuscarinico y un corticoesteroide - Google Patents

Medicamentos que comprenden un agente antimuscarinico y un corticoesteroide

Info

Publication number
AR058194A1
AR058194A1 ARP060105053A ARP060105053A AR058194A1 AR 058194 A1 AR058194 A1 AR 058194A1 AR P060105053 A ARP060105053 A AR P060105053A AR P060105053 A ARP060105053 A AR P060105053A AR 058194 A1 AR058194 A1 AR 058194A1
Authority
AR
Argentina
Prior art keywords
corticoesteroid
drugs
antimuscarinic agent
medicament
inflammatory
Prior art date
Application number
ARP060105053A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR058194A1 publication Critical patent/AR058194A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicacion 1: Un medicamento que comprende, en forma separada o en conjunto, (A) una sal de glicopirronio y (B) furoato de mometasona, para administracion simultánea, secuencial o separada en el tratamiento de una enfermedad inflamatoria u obstructiva de las vías respiratorias.
ARP060105053A 2005-11-21 2006-11-17 Medicamentos que comprenden un agente antimuscarinico y un corticoesteroide AR058194A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0523653.4A GB0523653D0 (en) 2005-11-21 2005-11-21 Organic compounds

Publications (1)

Publication Number Publication Date
AR058194A1 true AR058194A1 (es) 2008-01-23

Family

ID=35580402

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105053A AR058194A1 (es) 2005-11-21 2006-11-17 Medicamentos que comprenden un agente antimuscarinico y un corticoesteroide

Country Status (14)

Country Link
US (1) US20080317862A1 (es)
EP (1) EP1954266A1 (es)
JP (1) JP2009516662A (es)
KR (1) KR20080069196A (es)
CN (1) CN101312721A (es)
AR (1) AR058194A1 (es)
AU (1) AU2006314723A1 (es)
BR (1) BRPI0618807A2 (es)
CA (1) CA2630224A1 (es)
GB (1) GB0523653D0 (es)
PE (1) PE20071081A1 (es)
RU (1) RU2008124825A (es)
TW (1) TW200803840A (es)
WO (1) WO2007057222A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2435024T3 (en) 2009-05-29 2016-10-24 Pearl Therapeutics Inc Compositions for the respiratory delivery of active agents and related methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
TWI495468B (zh) 2009-12-23 2015-08-11 Chiesi Farma Spa 治療慢性阻塞性肺病（ｃｏｐｄ）之醫藥組成物
CN102665678B (zh) 2009-12-23 2014-07-02 奇斯药制品公司 用于copd的联合治疗
RU2018115685A (ru) 2011-02-17 2019-03-05 Сипла Лимитед Фармацевтическая композиция
FR2987266B1 (fr) * 2012-02-28 2014-12-19 Debregeas Et Associes Pharma Procede d'obtention d'une composition pharmaceutique a base de modafinil, composition pharmaceutique ainsi obtenue et son application
CA2897464C (en) * 2013-01-28 2021-05-18 Incozen Therapeutics Pvt. Ltd. Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
KR102377252B1 (ko) 2013-02-28 2022-03-22 저니 메디컬 코퍼레이션 글리코피롤레이트 염
WO2014144894A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
WO2015008205A2 (en) * 2013-07-13 2015-01-22 Mahesh Kandula Compositions and methods for the treatment of respiratory diseases
BR112016014583B1 (pt) 2013-12-30 2022-12-20 Chiesi Farmaceutici S.P.A Composição de solução farmacêutica em aerossol, inalador pressurizado de dose calibrada e uso da dita composição
TWI602566B (zh) 2014-09-09 2017-10-21 維克杜拉有限公司 調配物、方法及裝置
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
PE20221439A1 (es) 2019-12-02 2022-09-21 Chiesi Farm Spa Lata de acero inoxidable para inhaladores dosificadores presurizados

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3260474D1 (en) * 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
WO2002036106A2 (de) * 2000-10-31 2002-05-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittelkompositionen auf der basis von anticholingergika und corticosteroiden
DK1713473T3 (da) * 2004-02-06 2013-06-17 Meda Pharma Gmbh & Co Kg Kombination af anticholinergika og glucocorticoider til langtidsbehandling af astma og COPD
AU2005210086A1 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
CA2603433A1 (en) * 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist

Also Published As

Publication number Publication date
KR20080069196A (ko) 2008-07-25
TW200803840A (en) 2008-01-16
CA2630224A1 (en) 2007-05-24
EP1954266A1 (en) 2008-08-13
GB0523653D0 (en) 2005-12-28
US20080317862A1 (en) 2008-12-25
BRPI0618807A2 (pt) 2011-09-13
AU2006314723A1 (en) 2007-05-24
PE20071081A1 (es) 2007-12-11
CN101312721A (zh) 2008-11-26
RU2008124825A (ru) 2009-12-27
WO2007057222A1 (en) 2007-05-24
JP2009516662A (ja) 2009-04-23

Similar Documents

Publication Publication Date Title
AR058194A1 (es) Medicamentos que comprenden un agente antimuscarinico y un corticoesteroide
CL2007002526A1 (es) Un medicamento que comprende, separado o juntos: a) una sal de glicopirronio; b) un agonista del adreno-receptor beta-2 seleccionado de salmeterol y formoterol; y c) un corticosteroide; kit farmaceutico; y uso en el tratamiento de una enfermedad infl
CL2004001170A1 (es) Combinacion farmaceutica inhalable que contiene (a) formoterol, o una sal, o un solvato de el o de la sal y (b) furoato de mometasona; estuche farmaceutico que la comprende; y su uso en la terapia de una enfermedad inflamatoria u obstructiva de las v
AR057904A1 (es) Medicamentos que comprenden un agente antimuscerinico y un corticoesteroide
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
ID29181A (id) Kombinasi formoterol dan garam tiotropium
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
AR053026A1 (es) Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf)
AR022609A1 (es) Combinaciones de un agonista de beta-2 y un esteroide
WO2007057221A3 (en) Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases
AR065392A1 (es) Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio
CY1106430T1 (el) Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο
CR7152A (es) Un inhibidor de pde4 y un agente de anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias.
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
CL2007002875A1 (es) Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales.
AR054253A1 (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
MX2009011900A (es) Curacion de herida diabetica.
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
ECSP078014A (es) Regimen de dosificacion para prasugrel
CL2008000965A1 (es) Composicion farmaceutica que comprende un agente antiinflamatorio no esteroideo y un analgesico opiaceo, y su uso para el tratamiento del dolor.
UY27564A1 (es) Combinación farmacéutica.
CL2004000319A1 (es) Combinacion farmaceutica que comprende edotecarina o una sal farmaceuticamente aceptable y docetaxel o capacitabina, kit terapeutico, util para el tratamiento del cancer.
AR045177A1 (es) Uso de un compuesto tazaroteno para preparar una composicion farmaceutica de utilidad para tratar acne noduloquistico severo o grave
AR058328A1 (es) Uso de paliperidona para el tratamiento de un trastorno mental en un paciente psiquiatrico con funcionamiento hepatico reducido
UY27686A1 (es) Nuevas sales del ácido cinámico, procedimientos para su preparación y su utilización como medicamentos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal